EGFR and adenocarcinoma: Resistance mechanisms that bypass EGFR signaling, such as MET and HER2 amplification account for another 15%-20% of resistance to EGFR inhibitors and a less common mechanism is the histological transformation of EGFR-mutant adenocarcinoma to SCLC[63,64].